Browsing by Author "Erdogmus, Siyar"

Now showing 1 - 7 of 7

ANGIOTENSIN RECEPTOR BLOCKERS PROVIDE BETTER GLOMERULAR FILTRATION RATES THAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN KIDNEY TRANSPLANT RECIPIENTS WITH PROTEINURIA
(2020) Etlik, Zeynep Melekoglu; Sayin, Burak; Erdogmus, Siyar; Colak, Turan; Akdur, Aydincan; Haberal, Mehmet A.
CLINICAL FEATURES AND SENSITIZATION RISK FACTORS IN PATIENTS AWAITING KIDNEY TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
(2020) Erdogmus, Siyar; Celebi, Zeynep Kendi; Sayin, Burak; Acar, F. Nurhan Ozdemir; Karakaya, Emre; Haberal, Mehmet A.
INTRA-PATIENT TACROLIMUS LEVEL VARIABILITY IN BK VIRUS ASSOCIATED NEPHROPATHY
(2020) Turgut, Didem; Topcu, Deniz Ilhan; Erdogmus, Siyar; Ozdemir, F. Nurhan; Kirnap, Mahir; Haberal, Mehmet A.
The Mutation Identified in TWEAK-Fn14 Pathway May Affect the Clinical Course of IgA Nephropathy/Henoch-Schonlein Purpura Nephritis: A Case Report
(2021) Celebi, Zeynep Kendi; Turgut, Didem; Erdogmus, Siyar; Avsaroglu, Ezgi; Musabak, Haci Ugur; Colak, Turan
The TNF-like weak inducer of apoptosis (TWEAK) gene was first discovered in 1997 and its receptor Fn14 in 2001. TWEAK can be protective or damaging, depending on the status of the tissue. While basal TWEAK and Fn14 concentrations were found to be low in the kidney under normal conditions, TWEAK levels and tissue receptor expression were found to be increased in the presence of an acute injury.We report here the first case with persistent microscopic hematuria since infancy with TWEAK gene mutation, who was diagnosed with IgA Nephropathy/Henoch-Schonlein Purpura Nephritis at the age of 18 during a kidney biopsy. The genetic mutation in this patient may have caused a better course of the disease.
NT-proBNP level in stage 3-4 chronic kidney disease and mortality in long-term follow-up: HAPPY study subgroup analysis
(2020) Simsek, Mustafa Aytek; Degertekin, Muzaffer; Cabbar, Ayca Turer; Hunuk, Burak; Akturk, Serkan; Erdogmus, Siyar; Mutlu, Bulent; Kozan, Omer; 32633264
Objective: This was an investigation of the relationship between the N-terminal pro-brain natriuretic peptide (NT-proBNP) level and mortality in patients with stage 3-4 chronic kidney disease (CKD). Methods: This study was designed as a subgroup analysis of the Heart Failure Prevalence and Predictors in Turkey (HAPPY) study. The HAPPY study included 4650 randomly selected individuals from the 7 geographical regions of Turkey. A total of 191 subjects from the original cohort with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.1.73 m(2) were enrolled in this study and the relationship between NT-proBNP and mortality was investigated. Prognostic variables for total and cardiovascular mortality were also examined using Cox regression analysis. Results: The mean length of follow-up was 76.12 +/- 22.45 months. The mean NT-proBNP level was 423.54 +/- 955.88 pg/mL. During follow-up, 51 subjects (26.7%) died from any cause and 36 subjects (18.8%) died from a cardiovascular cause. The presence of hypertension (hazard ratio [HR]: 1.89; 95% confidence interval [CI]: 1.01-3.50; p=0.048), anemia (HR: 2.49; 95% CI: 1.20-5.15; p=0.014), male gender (HR: 2.64; 95% CI: 1.44-4.86; p=0.002) and log NT-proBNP (HR: 4.93; 95% CI: 2.83-8.58; p<0.001) were independent variables for total mortality. The presence of hypertension (HR: 2.47; 95% CI: 1.09-5.56; p=0.029), male gender (HR: 2.79; 95% CI: 1.38-5.62; p=0.004), eGFR (HR: 0.94; 95% CI: 0.91-0.98; p=0.005) and log NT-proBNP (HR: 6.31; 95% CI: 3.11-12.81; p<0.001) were independent predictors of cardiovascular mortality. Conclusion: NT-proBNP was found to be an independent prognostic marker in patients with stage 3-4 CKD.
Sensitization Status of Patients on the Deceased Donor Kidney Transplant Waiting List: A Single-Center Experience
(2022) Erdogmus, Siyar; Celebi, Zeynep Kendi; Turgut, Didem; Sayin, Burak; Ozdemir, Fatma Nurhan; Colak, Turan; Haberal, Mehmet; 0000-0002-3462-7632; AAJ-8097-2021
Objectives: This study aimed to analyze the features of patients on the deceased donor kidney transplant waiting list and risk factors associated with sensitization that affect panel reactive antibody status in our center. Methods: Patients' data were collected retrospectively. Panel reactive antibody screening and definition tests were studied for class I (A, B, and C) and class II (DR, DP, DQ) antigens with Luminex every 6 months. Patients with panel reactive antibody >5% and antibody strength >1000 median fluorescence intensity were considered panel reactive antibody-positive. Based on the panel reactive antibody status, the patients were divided into 2 groups: the panel reactive antibody-positive group and -negative group. Results: A total of 338 patients (60% male, mean age: 52.6 +/- 14.6 years) were included in the analysis. Panel reactive antibody positivity was detected in 117 (34.6) patients on the waiting list. Compared with the panel reactive antibody-negative patient group, the panel reactive antibody-positive patient group had higher rate of women and lower age (P <.001 and P <.001, respectively). The patients in the panel reactive antibody-positive group also had longer dialysis vintage (P =.027), higher rate of blood transfusion history (P <.001), organ transplant (P <.001), and higher number of blood transfusion (P <.001). Female gender (odd ratio:4.094, 95% CI:2.275-7.368, P <.001), history of blood transfusion (odds ratio:2.027, 95% CI:1.131-3.633, P =.018), and organ transplant (odds ratio:16.894, 95% CI:7.212-39.578, P <.001) were independent risk factors associated with panel reactive antibody positivity. Conclusion: Updates of the organ allocation system to consider sensitized patients and new strategies to expand the donor pool and donation rates are needed in Turkiye.
WHY CAN'T I HAVE A KIDNEY TRANSPLANT? LIMITATIONS TO DONATE KIDNEY OR TO HAVE ALLOGRAFT
(2020) Celebi, Zeynep Kendi; Erdogmus, Siyar; Acar, Nurhan Ozdemir; Soy, Ebru H. Ayvazoglu; Haberal, Mehmet A.